Physician profile
Ryan Smith
NPI 1659739399
$4,081.10
in general payments reported to CMS, 2019-2025
23 companies · $612 in 2025
The $612 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,485 · 2020: $289 · 2021: $117 · 2022: $593 · 2023: $223 · 2024: $761 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,594 · Education: $1.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,594.49 |
| Education | $1.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $944.43 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $624.22 | 2019-2025 | Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $312.39 | 2019-2025 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $270.59 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $212.70 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $208.76 | 2019-2025 | Invega Sustenna |
| Axsome Therapeutics, INC. | $207.93 | 2024 | Auvelity |
| Vanda Pharmaceuticals INC. | $195.38 | 2019-2024 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $195.13 | 2024-2025 | Cobenfy |
| Allergan, INC. | $183.17 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.62 | 2019-2025 | Trintellix |
| Acadia Pharmaceuticals INC | $96.57 | 2022 | |
| Abbvie INC. | $85.50 | 2022 | |
| Shire North American Group INC | $84.62 | 2019 | |
| Lundbeck LLC | $84.45 | 2019-2025 | Abilify Asimtufii |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $59.97 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.91 | 2021 | |
| Neos Therapeutics, Lp | $35.16 | 2019 | |
| Tris Pharma INC | $33.08 | 2025 | Dyanavel Xr |
| Corium, LLC | $31.46 | 2023-2025 | Azstarys |
| Vertical Pharmaceuticals, LLC | $22.75 | 2025 | Relexxii |
| Rhodes Pharmaceuticals L.P. | $18.35 | 2019 | |
| Indivior INC. | $16.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.